CURIS INC
CURIS INC (CRIS): 35 pipeline candidates · 4 upcoming catalysts · ~5 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
5.3 months
D/E 1.34 · 0% dilution
Lead: Phase 2/Phase 3
35 candidates
4 upcoming, next in ~1478d
1 buy · 0 sells (180d)
A transparent, data-derived signal for CURIS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$14.9M
Cash
$15.5M
Quarterly Burn
$9.0M
Runway
5.3 mo
Revenue
$0
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (35 candidates)
| Drug | Phase |
|---|---|
| Adavosertib | Phase 2 |
| Afatinib | Phase 2 |
| Afatinib Dimaleate | Phase 2 |
| Binimetinib | Phase 2 |
| CA-170 | Phase 2/Phase 3 |
| CA-327 | Preclinical |
| Capivasertib | Phase 2 |
| Copanlisib | Phase 2 |
| Copanlisib Hydrochloride | Phase 2 |
| Crizotinib | Phase 2 |
Showing 10 of 35 candidates. Sign up for full pipeline.
Upcoming Catalysts (4)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
36
Total value held
$2.3M
| Holder | Shares | Value |
|---|---|---|
| sphera funds management ltd. | 1,994,937 | $1.1M |
| vanguard capital management llc | 748,652 | $410K |
| renaissance technologies llc | 366,740 | $201K |
| morgan stanley | 254,245 | $139K |
| geode capital management, llc | 168,327 | $92K |
| cm management, llc | 150,000 | $82K |
| focused wealth management, inc | 109,746 | $60K |
| citadel advisors llc | 67,018 | $37K |
| boothbay fund management, llc | 62,168 | $34K |
| vanguard fiduciary trust co | 61,664 | $34K |
Showing top 10 of 36 institutional holders of CURIS INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in CURIS INC's pipeline?
CURIS INC (CRIS) has 35 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CURIS INC's lead drug candidate?
CURIS INC's most advanced tracked candidate is Adavosertib (Phase 2) for Advanced Lymphoma.
What is CURIS INC's next catalyst?
CURIS INC's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: GILOTRIF" — expected July 5, 2030.
What is CURIS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CURIS INC has approximately 5.3 months of cash runway.
What is CURIS INC's market capitalization?
CURIS INC's market capitalization is approximately $14.9M.
Get the full picture on CURIS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.